Clare Kahn

Jun 11, 2024 | investing.com | Clare Kahn

Clare Kahn, a director of Solid Biosciences Inc. (NASDAQ:), a company specializing in biological products, has recently made a purchase of company stock valued at approximately $8,441. The transaction took place on June 7, 2024, and involved acquiring 1,100 shares at a price of $7.6742 per share. This recent acquisition by Kahn has increased their direct ownership in the company to a total of 1,100 shares.

Jan 5, 2024 | thelancet.com | Qingwei Luo |Julia Steinberg |Clare Kahn |Michael Caruana

SummaryLong-term projections of premature mortality (defined as deaths age <75 years) help to inform decisions about public health priorities. This study aimed to project premature mortality rates in Australia to 2044, and to estimate numbers of deaths and potential years of life lost (PYLL) due to premature mortality overall and for 59 causes. We examined the past trends in premature mortality rates using Australian mortality data by sex, 5-year age group and 5-year calendar period up to 2019.